Latest Breaking News On - Maria yonkoski - Page 1 : vimarsana.com

Celcuity To Participate in Jefferies Global Healthcare Conference

MINNEAPOLIS, June 03, 2024 -- Celcuity Inc. , a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies...

Celcuity Announces Pricing of Underwritten Common Stock Offering

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line ...

Celcuity Inc. (NASDAQ:CELC) Q1 2024 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen. And welcome the Celcuity First Quarter 2024 Financial Results Conference call. At this time, all lines are in a listen-only mode.

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript

Celcuity Inc. beats earnings expectations. Reported EPS is $-0.65, expectations were $-0.71.

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

The Liver Meeting® 2023 showcasing the beneficial shift in lipid profile in denifanstat-treated patients End-of-Phase 2 meeting with U.S. Food and Drug Administration expected in first half of...

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

SAN MATEO, Calif., March 25, 2024 -- Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional...

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of ...

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional